Collaborative Arrangements (Tables)

9 Months Ended

Sep. 30, 2014

During the three and nine months ended September 30, 2014 and 2013, the Company recognized the following revenues attributable to the Janssen HCV collaboration:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
	(in thousands)
Royalty revenues (INCIVO)	$	2,284	$	20,994	$	12,917	$	104,108
Collaborative revenues:
Up-front and amendment payments revenues	$	—	$	3,107	$	—	$	9,321
Net reimbursement for telaprevir development costs	1,390		1,413		4,262		1,422
Reimbursement for manufacturing services	—		—		—		10,299
Total collaborative revenues attributable to the Janssen HCV collaboration	$	1,390	$	4,520	$	4,262	$	21,042
Total revenues attributable to the Janssen HCV collaboration	$	3,674	$	25,514	$	17,179	$	125,150

During the three and nine months ended September 30, 2014 and 2013, the Company recognized the following revenues attributable to the CFFT collaboration:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
	(in thousands)
Collaborative revenues attributable to the CFFT collaboration	$	1,983	$	3,515	$	6,455	$	11,318

Summary of activity related to net loss (income) attributable to noncontrolling interest (Alios)

A summary of net loss from discontinued operations attributable to noncontrolling interest (Alios) for the three and nine months ended September 30, 2013 is as follows:



	Three Months Ended September 30, 2013			Nine Months Ended September 30, 2013
	(in thousands)
Loss before benefit from income taxes	$	9,056		$	21,177
Decrease (increase) in fair value of contingent milestone and royalty payments	(1,220		)	1,600
Benefit from income taxes	(3,306		)	(9,089		)
Loss from discontinued operations attributable to noncontrolling interest (Alios)	$	4,530		$	13,688